Literature DB >> 30533819

Draft Genome Sequence of Escherichia Phage PGN829.1, Active against Highly Drug-Resistant Uropathogenic Escherichia coli.

Naveen Chaudhary1, Balvinder Mohan1, Neelam Taneja1.   

Abstract

The Escherichia phage PGN829.1 was isolated from sewage of a tertiary care referral hospital in North India. It lyses multiple strains of highly drug-resistant uropathogenic E. coli. It belongs to the family Podoviridae. Its genome is closest to that of Escherichia phage Vb_EcoP_PhAPEC7.

Entities:  

Year:  2018        PMID: 30533819      PMCID: PMC6256618          DOI: 10.1128/MRA.01141-18

Source DB:  PubMed          Journal:  Microbiol Resour Announc        ISSN: 2576-098X


ANNOUNCEMENT

Here, we report an annotated genome sequence of Escherichia phage PGN829.1, which is capable of lysing multiple strains of highly drug-resistant uropathogenic Escherichia coli (UPEC), which is resistant to cefotaxime, cefoperazone, amikacin, gentamicin, nitrofurantoin, nalidixic acid, ciprofloxacin, imipenem, co-trimoxazole, tazobactam-piperacillin, and cefoperazone-sulbactam. This phage was isolated from a sewage discharge of a 2,000-bed tertiary care referral center at the Postgraduate Institute of Medical Education and Research in Chandigarh, India. We used an enrichment procedure involving a spot assay and soft agar plaque assay (1). A single plaque 2 mm in diameter was picked up with a micropipette tip and transferred into 1 ml of SM buffer (10 mM MgSO4 · 6H2O) followed by vortexing to release the phages from the agar plug (2). We amplified the phage by adding 4 ml of broth culture of the host bacterial strain to 100 µl of the phage content and incubating for 24 h at 37°C. The phage was purified by ultracentrifugation with polyethylene glycol 8000 (Sigma-Aldrich, USA) and dialysis with dialysis membrane 110 (HiMedia Laboratories, India) (3). We tested the host range of PGN829.1 against multiple clinical isolates of highly drug-resistant UPEC and found it to be active against multiple UPEC strains (Table 1). We extracted the phage genomic DNA with a phage DNA isolation kit (Norgen Biotek, Canada) (4). The DNA quality was assessed using a NanoDrop 8000 spectrophotometer (Thermo Scientific, USA), and the concentration was estimated using a Qubit 3.0 fluorometer (Life Technologies, USA). An Illumina sequencing library of genomic DNA was prepared using a NEBNext Ultra library preparation kit, and sequencing was performed on an Illumina HiSeq 2500 sequencer, which generated 8,115,440 paired-end raw reads that were 100 bp long. The genome was sequenced to an average depth of 100×. De novo assembly was performed using Iterative Virus Assembler (IVA) version 1.0.8 (5). The FastQ files were preprocessed before performing assembly. Adapter sequences were trimmed with Cutadapt and Sickle, and we filtered out reads with an average quality score of less than 30 in any of the paired-end reads (6). We predicted genes from the IVA-assembled contigs using GLIMMER 3 software. The predicted genes were annotated using our in-house contig annotation pipeline (CANoPI) and followed a three-step procedure, (1) comparison with the UniProt database using the BLASTx program, (2) organism annotation, and (3) gene ontology (GO) annotation. In the first step, the predicted genes with an E value cutoff of 10−3 and identity cutoff of 40% were retained for further annotation. A total of 87 open reading frames were predicted, out of which 84 could be annotated based on significant hits in the UniProt database. The GO terms molecular function (MF), cellular component (CC), and biological process (BP) for genes were mapped using the Blast2Go tool (7). A BLASTn similarity search revealed that the genome of PGN829.1 is closest to Escherichia phage Vb_EcoP_PhAPEC7 (GenBank accession number KF562340), which belongs to a family of noncontractile short-tailed phages known as Podoviridae (8). Phage PGN829.1 has a genome size of 74.4 kb and a GC content of 42.9%. We conclude that the lytic activity shown by Escherichia phage PGN829.1 against highly drug-resistant UPEC strains may have potential therapeutic value for treating urinary tract infections.
TABLE 1

Antibiotic resistance profile of UPEC strains lysed by Escherichia phage PGN829.1

StrainCTXCFPGENAMKNALNORCIPSXTNITIPM TZPCFP-SULPMB
E. coli 42829RRSSRRRRRSRRS
E. coli 13879RRRRRRRRSRRRR
E. coli 15286RRRRRRRRSRRRR
E. coli 14075RRRRRRRRSRRRR

CTX, cefotaxime; CFP, cefoperazone; GEN, gentamycin; AMK, amikacin; NAL, nalidixic acid; NOR, norfloxacin; CIP, ciprofloxacin; SXT, co-trimoxazole; NIT, nitrofurantoin; IPM, imipenem; TZP, tazobactam-piperacillin; CFP-SUL, cefoperazone-sulbactam; PMB, polymyxin B; R, resistant; S, susceptible.

Antibiotic resistance profile of UPEC strains lysed by Escherichia phage PGN829.1 CTX, cefotaxime; CFP, cefoperazone; GEN, gentamycin; AMK, amikacin; NAL, nalidixic acid; NOR, norfloxacin; CIP, ciprofloxacin; SXT, co-trimoxazole; NIT, nitrofurantoin; IPM, imipenem; TZP, tazobactam-piperacillin; CFP-SUL, cefoperazone-sulbactam; PMB, polymyxin B; R, resistant; S, susceptible. This study was approved by the Institute Ethical Clearance Committee of PGIMER, Chandigarh.

Data availability.

The raw sequence reads have been submitted to the NCBI SRA under accession number PRJNA495477, and the draft genome sequence of Escherichia coli phage PGN829.1 has been deposited in NCBI GenBank under accession number MH733496.
  8 in total

Review 1.  A common evolutionary origin for tailed-bacteriophage functional modules and bacterial machineries.

Authors:  David Veesler; Christian Cambillau
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

2.  Isolation and characterization of bacteriophages from fermenting sauerkraut.

Authors:  S S Yoon; R Barrangou-Poueys; F Breidt; T R Klaenhammer; H P Fleming
Journal:  Appl Environ Microbiol       Date:  2002-02       Impact factor: 4.792

3.  Complete genome of Staphylococcus aureus phage SA11.

Authors:  Min Soo Kim; Heejoon Myung
Journal:  J Virol       Date:  2012-09       Impact factor: 5.103

4.  In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy.

Authors:  Sandra Chibani-Chennoufi; Josette Sidoti; Anne Bruttin; Elizabeth Kutter; Shafiq Sarker; Harald Brüssow
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

5.  IVA: accurate de novo assembly of RNA virus genomes.

Authors:  Martin Hunt; Astrid Gall; Swee Hoe Ong; Jacqui Brener; Bridget Ferns; Philip Goulder; Eleni Nastouli; Jacqueline A Keane; Paul Kellam; Thomas D Otto
Journal:  Bioinformatics       Date:  2015-02-28       Impact factor: 6.937

6.  Sequencing, De Novo Assembly, and Annotation of the Transcriptome of the Endangered Freshwater Pearl Bivalve, Cristaria plicata, Provides Novel Insights into Functional Genes and Marker Discovery.

Authors:  Bharat Bhusan Patnaik; Tae Hun Wang; Se Won Kang; Hee-Ju Hwang; So Young Park; Eun Bi Park; Jong Min Chung; Dae Kwon Song; Changmu Kim; Soonok Kim; Jun Sang Lee; Yeon Soo Han; Hong Seog Park; Yong Seok Lee
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

7.  Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy.

Authors:  Mohammadali Khan Mirzaei; Anders S Nilsson
Journal:  PLoS One       Date:  2015-03-11       Impact factor: 3.240

8.  Assessing Illumina technology for the high-throughput sequencing of bacteriophage genomes.

Authors:  Branko Rihtman; Sean Meaden; Martha R J Clokie; Britt Koskella; Andrew D Millard
Journal:  PeerJ       Date:  2016-06-01       Impact factor: 2.984

  8 in total
  1 in total

1.  Whole genome sequencing and in vitro activity data of Escherichia phage NTEC3 against multidrug-resistant Uropathogenic and extensively drug-resistant Uropathogenic E. coli isolates.

Authors:  Naveen Chaudhary; Dharminder Singh; Ravi Kumar Maurya; Balvinder Mohan; Ravimohan S Mavuduru; Neelam Taneja
Journal:  Data Brief       Date:  2022-07-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.